Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Scribd Logo
Upload

Welcome to Scribd!

  • 36 views

    BGI ServiceOverview SENTIS Cancer+Discovery

    Uploaded by

    pirachat.pira
    This document summarizes BGI's SENTISTM Cancer+Discovery panel, which provides comprehensive genomic profiling of 688 cancer-related genes from tissue or liquid biopsy samples. Key features include whole exon sequencing, interpretation of mutations in the context of over 200 drugs, and discovery of novel variants. The panel also evaluates risk for hereditary cancers and includes genes related to cancer pathways. Technical details are provided on sensitivity and limits of detection for different mutation types. Sample requirements and turnaround times are listed.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    BGI ServiceOverview SENTIS Cancer+Discovery

    Uploaded by

    pirachat.pira
    36 views2 pages
    This document summarizes BGI's SENTISTM Cancer+Discovery panel, which provides comprehensive genomic profiling of 688 cancer-related genes from tissue or liquid biopsy samples. Key features include whole exon sequencing, interpretation of mutations in the context of over 200 drugs, and discovery of novel variants. The panel also evaluates risk for hereditary cancers and includes genes related to cancer pathways. Technical details are provided on sensitivity and limits of detection for different mutation types. Sample requirements and turnaround times are listed.

    Original Description:

    SENTIS Cancer+Discovery

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    This document summarizes BGI's SENTISTM Cancer+Discovery panel, which provides comprehensive genomic profiling of 688 cancer-related genes from tissue or liquid biopsy samples. Key features include whole exon sequencing, interpretation of mutations in the context of over 200 drugs, and discovery of novel variants. The panel also evaluates risk for hereditary cancers and includes genes related to cancer pathways. Technical details are provided on sensitivity and limits of detection for different mutation types. Sample requirements and turnaround times are listed.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    36 views2 pages

    BGI ServiceOverview SENTIS Cancer+Discovery

    Uploaded by

    pirachat.pira
    This document summarizes BGI's SENTISTM Cancer+Discovery panel, which provides comprehensive genomic profiling of 688 cancer-related genes from tissue or liquid biopsy samples. Key features include whole exon sequencing, interpretation of mutations in the context of over 200 drugs, and discovery of novel variants. The panel also evaluates risk for hereditary cancers and includes genes related to cancer pathways. Technical details are provided on sensitivity and limits of detection for different mutation types. Sample requirements and turnaround times are listed.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    of 2

    Gain insight into clinically

    actionable mutations and


    discover new treatment targets
    with one of the market’s most Introduction
    comprehensive and affordable
    Technological advances combined with
    panels. improved understanding of the genetic basis of
    cancer has revolutionized the way we manage
    cancer. Utilizing patient’s particular genomic
    profile, clinicians can now assess the risk of
    hereditary cancer for the patient and patient’s
    family, as well as tailor the best treatment
    options.

    BGI’s SENTIS™ Cancer+Discovery provides


    clinicians with one of the market’s most
    comprehensive and accurate Next Generation
    Sequencing (NGS) based testing solution for the
    identification of clinically actionable mutations,
    as well as discovery of novel variants with
    important function in cancer. Supporting both
    tissue sample and liquid biopsy, the panel offers
    whole exon coverage of 688 cancer-related
    genes and interrogates most common types of
    alterations including SNVs, indels, CNVs and
    fusions in solid tumors.

    The Power of Knowing


    BGI SENTIS™ Cancer+Discovery (Tissue/ctDNA)

    Advantages
    Comprehensive - Whole exon coverage of 688 cancer-related genes, supporting most common types of genomic alterations
    including base substitutions, InDel, CNV, fusion,TMB and MSI
    - Includes genes associated with both sporadic and hereditary cancers
    - Provides interpretation on the therapeutic relevance in 200+ drugs, including 260 targeted therapies (both
    approved and currently in clinical trial), 11 immunotherapies and 11 commonly used chemotherapies
    - Includes 425 genes in cancer-related pathways for discovery of novel pathogenic variants

    Flexible - BGI SENTIS™ Cancer+Discovery (Tissue): matched fresh tissue, biopsy, FFPE, DNA and peripheral blood
    - BGI SENTIS™ Cancer+Discovery (ctDNA): peripheral blood or DNA

    Reliable - See technical information for details.

    Liquid biopsy version allows genetic profiling in situations where tissue is not available or continuous monitoring
    of tumor molecular profile is required.
    The Power of Knowing
    BGI SENTIS™ Cancer+Discovery (Tissue/ctDNA)

    Gene Panel Overview Workflow

    Counselling and
    Colon
    Pancreatic MSI 182 Interpretation Consent
    carcinoma Therapy for more than
    Cancer
    Target Genes 200 drugs Sample Collection
    Breast
    Cancer DNA Extraction
    Ovarian 63 Evaluate and QC
    Cancer 688 Hereditary the risk for Targeted Capture
    Cancer herediatary
    Hepatobiliary
    carcinoma
    genes Genes cancer
    and NGS
    Gastric
    Cancer
    Data Analysis and
    425 Discover Interpretation
    Cancer genes potentially
    Prostate Lung TMB Pathway important in drug Report Ready
    Cancer Cancer Genes target and
    resistance
    Genetic Counselling

    Technical Information

    SENTIS Cancer+Discovery(Tissue) Limit of Detection(LoD) Positive Predicttive Value(PPV) Sensitivity

    Single Nucleotide Variations(SNV) 1% 100% 99.2%

    Indels 0.5% 93% 97.8%

    Copy Number Amplifications(CNV) 3.4 copies 100% 100%

    Splice Variants(SV) 0.5% 100% 100%

    SENTIS Cancer+Discovery(ctDNA) Limit of Detection(LoD) Positive Predicttive Value(PPV) Sensitivity

    SNV 0.6% 97.30% 98.3%

    Indels 0.59% 100% 100%

    CNV 3.5 copies 100% 100%

    SV 1.25% 100% 100%

    Sample Requirements Ordering Information


    BGI SENTIS™ Cancer+Discovery (Tissue)
    ITEM CATALOG NO.
    - >60mg tissue or 15 FFPE 10mm*10mm (5-10µm) sections or ≥3 samplings of
    biopsy or ≥3µg good quality, tumor DNA; BGI SENTIS™
    - 5mL of peripheral blood Cancer+Discovery DX0643
    (Tissue)
    BGI SENTIS™ Cancer+Discovery (ctDNA) BGI SENTIS™
    - ≥10mL of peripheral blood (separated plasma and formed elements) or ≥8mL of Cancer+Discovery DX0644
    peripheral blood collected in Streck Cell-Free DNA BCT® tube (ctDNA)

    Turnaround Time
    Contact your local BGI representative for more information or email
    20 days (from sample arriving at BGI lab to
    info@bgi.com. More information can also be found on our website. report)
    www.bgi.com/global/

    Copyright© 2020 BGI. The BGI logo and SENTIS logo are trademarks of BGI. All rights reserved. Published January 2020, version 1.0
    For Research Use Only. Not for use in diagnostic procedures.
    Testing services not currently available in the United States of America. Please contact a representative for regional availability.

    You might also like